Monte Rosa Therapeutic (GLUE) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Platform and strategy

• Focus on targeted protein degradation using molecular glue degraders, leveraging the proprietary QuEEN platform that integrates AI, machine learning, and in-house experimentation.

• Expanded beyond oncology to autoimmune, cardiovascular, metabolic, and genetic diseases, with a strong financial runway into 2028.

• Portfolio includes differentiated programs built over five to six years, with ongoing expansion into new ligases and disease areas.

Key clinical programs and milestones

• MRT-2359 (GSPT1 degrader) in phase 1 for MYC-driven cancers, including prostate and ER-positive breast cancer, with additional data expected in Q1.

• MRT-6160 (VAV1 degrader) in phase 1 for autoimmune diseases, partnered with Novartis, with top-line results anticipated in Q1 and up to $2.1B in milestones.

• NEK7 degrader approaching IND filing in the first half of the year, targeting inflammatory conditions with high selectivity and long-lasting effects.

• CDK2 and Cyclin E1 degraders advancing toward development candidates for ovarian and ER-positive breast cancers, with strong preclinical and in vivo efficacy.

Scientific and clinical highlights

• Molecular glue degraders enable targeting of previously undruggable proteins with high selectivity and oral bioavailability.

• GSPT1 program shows promise in overcoming drug resistance in prostate cancer and is expanding to larger, less preselected patient populations.

• VAV1 program offers a multi-cytokine approach to autoimmune disease, with ex vivo biomarker analysis and potential for patient-friendly dosing.

• NEK7 degrader demonstrates monoselectivity and robust functional inhibition of the inflammasome pathway, with potential advantages over NLRP3 inhibitors.